High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234

Annals of Oncology

Volumn 10, Issue 5, 1999, Pages 597-600

  Vogelzang, N J ^a   Herndon II, J E ^b   Miller, A ^c   Strauss, G ^d   Clamon, G ^e   Stewart, F M ^f   Aisner, J ^g   Lyss, A ^h   Cooper, M R ⁱ   Suzuki, Y ^j   Green, M R ^k  

^a UNIVERSITY OF CHICAGO   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF MARYLAND   (United States)

^h MISSOURI BAPTIST MEDICAL CENTER   (United States)

ⁱ WAKE FOREST SCHOOL OF MEDICINE   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

more..

Author keywords

Mesothelioma; Paclitaxel

Indexed keywords

AZACITIDINE; CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRIMETREXATE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT MESOTHELIOMA; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE;

EID: 0032975150     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1023/A:1026438215309     Document Type: Article

References (13)

1. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: A review. J Clin Oncol 1996; 14 (3): 1007-17.
2. Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992; 65: 956-60.
3. Chahinian AP, Antman K, Goutsou M et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the CALGB. J Clin Oncol 1993; 11: 1559-65.
4. Vogelzang NJ, Goustou M, Corson JM et al. Carboplatin in malignant mesothelioma: A phase II study of the CALGB. Cancer Chem Pharm 1990; 27: 239-42.
5. Vogelzang NJ, Weissman LB, Herndon JE et al. Trimetrexate in malignant mesothelioma: A CALGB phase II study. J Clin Oncol 1994; 12(7): 1436-42.
6. Vogelzang NJ, Herndon JE II, Cirrincione C et al. Dihydro-5-azacytidine in malignant mesothelioma: A phase II trial demonstrating activity but with cardiac toxicity. Cancer 1997; 79: 2237-42.
7. Samuels BL, Herndon JE, Harmon DC et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B. Cancer 1998; 82: 1578-84.
8. Millard FF, Herndon J, Vogelzang NJ, Green MR. Gemcitabine for malignant mesothelioma (MM): A phase II study of the Cancer and Leukemia Group B (CALGB 9530). Proc Am Soc Clin Oncol 1997; 16: 1710.
9. Herndon JE, Green MR, Chahinian P et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113:723-31.
10. Curran D, Sahmoud T, Therasse P et al. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer Experience. J Clin Oncol 1998; 16 (1): 145-52.
11. Van Meerbeeck J, Debruyne C, van Zandwijk N et al. Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996; 74: 961-3.
12. Chahinian AP, Mandell JP, Gluck H et al. Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. J Surg Oncol 1998; 67: 104-11.
13. Kearns CM, Egorin MJ. Considerations regarding the less-thanexpected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol 1997; 24 (Suppl 2): 5191-296.